An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced malignancies
A study for patients with solid tumor and malignant lymphomas using study drug BAY 1143572
Sponsor: Bayer
Enrolling: Male and Female Patients
IRB Number: AAAO2313
U.S. Govt. ID: NCT01938638
Contact: Palak Thaker: 212-305-2055 /
Additional Study Information: The primary purpose of this research study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572. Moreover, concentrations of BAY 1143572 as well as of biomarker proteins may provide information about the effects of BAY 1143572, will be determined in blood and tumor tissue.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Have you been diagnosed with an advanced cancer such as solid tumors and malignant lymphomas? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Palak Thaker